论文部分内容阅读
目的探讨阿托伐他汀干预对急性冠脉综合征(ACS)患者血浆C反-应蛋白(CRP)和白介素-6(IL-6)水平的影响。方法采用随机开放法将62例ACS分为阿托伐他汀治疗组和常规对照组进行为期4周的干预,分别测定治疗前及治疗后2周患者血浆CRP和IL-6的浓度变化,比较治疗前后的血浆CRP及IL-6水平变化。结果急性冠脉综合征患者血清CRP及IL-6水平明显升高,治疗4周后,阿托伐他汀治疗组血浆CRP及IL-6水平均明显下降,而常规对照组CRP和IL-6水平无明显变化。结论ACS的发生与机体炎症反应激活有关。阿托伐他汀能够降低血浆CRP和IL-6水平,在ACS的治疗中具有重要作用。
Objective To investigate the effects of atorvastatin on plasma C-reactive protein (CRP) and interleukin-6 (IL-6) levels in patients with acute coronary syndrome (ACS). Methods 62 cases of ACS were randomly divided into atorvastatin group and routine control group for 4 weeks. The levels of CRP and IL-6 in plasma were measured before and 2 weeks after treatment. Changes in plasma CRP and IL-6 levels before and after treatment. Results Serum levels of CRP and IL-6 were significantly increased in patients with acute coronary syndrome. After 4 weeks of treatment, the levels of plasma CRP and IL-6 in atorvastatin group were significantly decreased, while CRP and IL-6 levels in normal control group No significant changes. Conclusion The occurrence of ACS is related to the activation of inflammatory reaction in the body. Atorvastatin can reduce plasma CRP and IL-6 levels and play an important role in the treatment of ACS.